Introduction
============

Anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC) take origin from the follicular cells but during the process of tumoral transformation, they lose progressively the typical features of these cells, being the ATC completely undifferentiated while PDTC showing an intermediate spectrum of differentiation ([@b1-ol-0-0-8470],[@b2-ol-0-0-8470]). These tumors, although rare (about 2 and 5% of thyroid cancer cases, respectively) ([@b3-ol-0-0-8470]), represent the most aggressive thyroid tumors but their median survival time is rather different being of 6--12 months and 3--5 years for ATC and PDTC, respectively ([@b4-ol-0-0-8470],[@b5-ol-0-0-8470]).

The histological diagnosis of ATC and PDTC is not always straightforward ([@b6-ol-0-0-8470]) and some controversial issues regarding the differential diagnosis among ATC and PDTC are not yet fully resolved by pathologists ([@b7-ol-0-0-8470]). However, at least two or three histological classifications to better distinguish these two types of advanced thyroid tumors have been proposed and the one chosen by the pathologist for the diagnosis should be indicated in the pathological report ([@b8-ol-0-0-8470],[@b9-ol-0-0-8470]).

Molecular alterations causative of these tumors have been studied over the years by Sanger analysis and/or other techniques ([@b10-ol-0-0-8470],[@b11-ol-0-0-8470]). Very recently the genomic and transcriptomic landscape of ATC and PDTC has been studied with a Next Generation Sequencing (NGS) approach ([@b12-ol-0-0-8470]). This study demonstrated that ATC, and to a lesser extent PDTC, are characterized by the accumulation of several different oncogenic alterations. In particular, so far, no genetic mutations or chromosomal rearrangements have been demonstrated to be unique for ATC and/or PDTC but, it is worth to note, that the majority of these studies are affected by the lack of using common histologic criteria to define either ATC or PDTC ([@b13-ol-0-0-8470]). In both cases the two most frequently altered genes are *TERT* oncogene and *TP53* tumor suppressor gene. However, while the prevalence of the mutations of the two genes is very high in ATC (i.e., 70--75%) they are much lower, especially for *TP53*, in PDTC (i.e., 40 and 8%, for *TERT* and *TP53*, respectively). Mutations of other genes that impair the MAPK and PI3K-AKT pathways including *BRAF, RAS, AKT, PTEN* and *PIK3CA* have been also reported with a prevalence higher than 10% at least in one of the two hystotypes ([@b12-ol-0-0-8470]). Other novel and rare (i.e., prevalence \<10%) gene\'s alterations have been also reported in NGS studies on ATC ([@b14-ol-0-0-8470],[@b15-ol-0-0-8470]) but their tumorigenic driving role is still undefined.

Tumor associated macrophages (TAMs) have been described in human cancer and their presence in tumoral tissues has been correlated with an advanced stage of the disease and a worse prognosis ([@b16-ol-0-0-8470]--[@b18-ol-0-0-8470]). A high density of TAM has been previously reported also in thyroid carcinomas with a higher density in ATC and PDTC with respect to well differentiated papillary thyroid cancer (PTC) ([@b19-ol-0-0-8470],[@b20-ol-0-0-8470]).

The aim of the present study was to verify if, in the clinical practice, ATC and PDTC diagnosed by our pathologist according to the WHO ([@b21-ol-0-0-8470]) and Turin classification ([@b6-ol-0-0-8470]) respectively, show a different clinical-pathological profile at diagnosis, a different oncogenic profile, and a different pattern of macrophage infiltration. The correlation between the somatic alterations and the survival time of the patients has been also explored.

Materials and methods
=====================

### Patients and tissue samples

Forty-two patients affected with ATC (n=21) or PDTC (n=21) were diagnosed and followed at the Endocrine Unit of the Department of Clinical and Experimental Medicine, University Hospital of Pisa (Pisa, Italy), from 2006 to 2016. We analyzed the thyroid tumoral DNA from all included patients. Thirty-one tissues were obtained at surgery, immediately frozen in liquid nitrogen and stored at −80°C until extraction; 4 samples derived from formalin fixed paraffin embedded (FFPE) tissues. Seven samples were derived from fine-needle aspiration (FNA) biopsies; FNA was performed under echo guidance by a skilled endocrinologist and using a 23-gauge needle attached to a 10-ml syringe. The aspirated material was used to prepare slides for cytological analysis. The left over cells were recovered in an appropriate buffer for DNA extraction and stored at −80°. In 6 cases normal thyroid tissue and/or blood was available. Clinical data were recorded in a computerized data base and analyzed according to the presence of genetic alterations.

A signed informed consent was obtained from all patients and the study received the approval of the Institutional Reviewing Board.

### Pathological diagnosis

Patients underwent total or subtotal thyroidectomy at the Department of Surgery of the University of Pisa, Italy. A pre-surgical cytological diagnosis of ATC or PDTC was available for all patients. Hematoxylin-eosin stained sections of all patients from the archives of the section of Pathology of the University of Pisa were re-evaluated independently by two pathologists (C.U. and F.B.). According to the 'Turin proposal' ([@b6-ol-0-0-8470]) PDTC have been defined as a neoplasm derived from follicular epithelial cells with specific characteristics, that are: i) a solid/trabecular/insular growth pattern; ii) the absence of conventional nuclear features of PTC; and iii) the presence of other features, such as convoluted nuclei, mitotic activity (≥3 mitoses per 10 HPF), or necrosis. Compared to ATC, PDTC shows a monotonous cell population and lack of significant pleomorphism or marked atypia of the nuclei. Moreover, necrosis is typically less prominent in PDTC, usually in focal areas, as compared with the geographic distribution in ATC. Since the immunophenotype is fundamental for the distinction between ATC and PDTC, the immunohistochemistry (IHC) for keratins, thyroglobulin (Tg) and thyroid transcription factor-1 (TTF-1) was performed following standard procedures ([@b22-ol-0-0-8470]) and the diagnosis took into account the evidence that keratins, Tg and TTF-1 are strongly expressed in well-differentiated carcinomas but typically less intense in PDTC, with Tg and TTF-1 that are completely lost in ATC, that retain only focal and weak expression of keratins.

### Genomic DNA and RNA extraction, PCR amplification and sequencing

About 30--40 mg of frozen tissue and the left over cells of FNA were used for genomic DNA extraction using the Maxwell^®^ 16 Tissue DNA Purification Kit (Promega Corporation, Madison, WI, USA). Genomic DNA was eluted in 300 µl of water. For FFPE tissues, one or two 5 µm sections were deparaffinized and digested with proteinase K overnight. DNA extraction was performed using the Maxwell^®^ 16 FFPE Tissue LEV DNA Purification Kit (Promega Corporation). DNA was finally diluted in 50--100 µl of water. DNA concentration was measured using an UV spectrophotometer (SmartSpec Plus Spectrophotometer; Bio-Rad Laboratories, Inc., Hercules, CA, USA), and 30 ng of genomic DNA was used for PCR in a final volume of 20 µl using a master mix (Kapa2G fast hs ready mix; Resnova S.r.l., Genzano di Roma, Italy).

Primers and PCR conditions were specially defined to the purpose of the present study ([Table I](#tI-ol-0-0-8470){ref-type="table"}). The amplified DNA was analyzed on 2% agarose gels and purified using a commercial kit (Jetquick purification kit; Celbio, Milan, Italy). Sequence analysis was performed with an automated system employing fluorescent dye terminators (ABI Prism 3110; PerkinElmer, Inc., Waltham, MA, USA). Hot spot positions of *NRAS, HRAS, KRAS, BRAF, AKT, PIK3CA, PTEN, TP53*, and *TERT* oncogenes have been sequenced in this study.

### Cloning of the deletions

The PCR product of the sample characterized by the presence of heterozigous deletions has been subjected to direct cloning by using the TA cloning Kit (TOPO^®^-TA cloning; Invitrogen; Thermo Fisher Scientific, Inc.) according to the instruction of the manufacturer.

### IHC for CD68

In order to investigate the presence of macrophage in tumoral samples, CD68 expression was evaluated by *IHC* on FFPE tumor sections using mouse monoclonal anti-human antibody (Ventana Medical Systems, Inc., Tucson, AZ, USA). Sections were stained using the Ventana automated slide stainer (Ventana Medical Systems, Inc.). Expression of CD68 was evaluated independently by two of the authors (C.U. and F.B.) who were both blinded to the clinicopathologic data. Discrepancies between the two observers were discussed with a third pathologist (L.T.). The authors evaluated the CD68 expression in macrophages. The samples were evaluated as positive if staining was present. The intensity of the staining was evaluated in 5 high power fields (×40 magnification) and the ratio between the number of CD68 macrophages positive cells and the number of tumoral cells of the samples (i.e., 1:1 and 1:10) was used to create a graduated score: Low (1:100, 1:200), Medium (1:50, 1:20), and High (1:1, 1:2, 1:3, 1:5).

### Statistical analysis

The statistical analysis was performed with the Chi-square test according to the studied variables. Survival curves were analyzed using the Kaplan-Meier method and the statistical significance was assessed by log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinico-pathological features of the studied patients

The mean age at diagnosis of the 21 ATC patients (10 males, 11 females) was 65.7 years (median 67, range 45--84). Clinico-pathological data were available in 17/21 patients. According to the TNM classification ([@b23-ol-0-0-8470]), 2 patients had a stage IVA disease (T4aN0-1M0), 4 a stage IVB (T4bN0-1M0) and 11 a stage IVC (T1-4N0-1M1). Among the 21 patients, 4 were lost at follow-up, 2 were free of disease, 1 had persistent disease and 14 were dead for the tumor with a median survival time of 6 months.

The mean age at diagnosis of the 21 PDTC patients (9 males, 12 females) was 60.2 years (median 58, range 41--83). Clinico-pathological data were available in 17/21 patients; According to the TNM classification ([@b23-ol-0-0-8470]), 2 patients had a stage II disease (T2N0M0), 1 a stage III (T1-3N0-1M0), 11 a stage IVA (T4aN0-1M0) and 1 a stage IVC (T1-4N0-1M1). For 2 patients that were not surgically treated at our hospital, the presence of node and distant metastases at diagnosis was not known. Among the 21 patients, 4 were lost at follow-up, 4 had persistent disease and 13 were dead for the tumor and the median survival was 47 months.

When comparing the clinical and pathological features of the 2 groups we found that, although not significantly, ATC patients were older than PDTC patients (median 67 vs. 58 years, respectively). Moreover ATC patients had distant metastases at diagnosis much more frequently than PDTC patients (stage IVC 11/17 vs. 1/17, respectively). Finally, although there was no difference in the final outcome in terms of deaths, the median time of survival was significantly shorter in ATC than in PDTC (median survival time 6 vs. 47 months, respectively; P=0.0014).

### Analysis of somatic mutations

All cases, 21 ATC and 21 PDTC, were screened for gene alterations in 10 selected genes. Overall 44 somatic alterations (40 point mutations and 4 deletions/insertions) were identified in the whole series. [Table II](#tII-ol-0-0-8470){ref-type="table"} shows detailed information on the type of mutations and their prevalence in our series.

In the whole series 25/42 (59.5%) cases were found to harbor at least 1 somatic alteration ([Fig. 1A](#f1-ol-0-0-8470){ref-type="fig"}) and 17/42 (40.5%) were found to be negative for the tested mutations. Moreover, in this series, multiple alterations in the same sample were found in several cases (n=13). In the ATC series ([Fig. 1B](#f1-ol-0-0-8470){ref-type="fig"}) a total of 15/21 (71.4%) cases were found to harbor at least 1 somatic alteration and 6/21 (28.6%) were found to be negative for the tested mutations. In this group, mutations of *TP53* were the most frequently found (10/21, 47.6%). In addition to *TP53* mutations, we found mutations in *TERT* (9/21, 42.8%), *PTEN* (4/21, 19%), *BRAF* (4/21, 19%), *N-RAS* (2/21, 9.5%), and *PIK3CA* (1/21, 4.7%). In the PDTC series a total of 10/21 (47.6%) cases were found to harbor at least 1 somatic alteration and 11/21 (52.4%) were found to be negative for the tested mutations. Mutations were found in *TERT* (7/21, 33.3%), *BRAF* (4/23, 19%), *N-RAS* (1/23, 4.7%), *AKT* (1/23, 4.7%) and *PIK3CA* (1/23, 4.7%) ([Fig. 1C](#f1-ol-0-0-8470){ref-type="fig"}). No mutations were found in *TP53* tumor suppressor gene in our PDTC.

Four ATC cases, already included in the above mentioned mutated cases, harbored complex alterations. Two of them were found in the *PTEN* tumor suppressor gene, the first in exon 5 that was characterized by a 1 bp interstitial deletion (c.355delG, p.V119Lfs\*15; COSM28903) and a missense mutation at codon 97 (Q97R) on the same allele; the second was in exon 7 (c.741_742insA, p.P248fs\*5; COSM4986). In 2 cases we found deletions in the *TP53* tumor suppressor gene: an in frame 3 bp deletion in the exon 6 (c.572_574delCTC, P191delP, COSM111721) and a never reported deletion in exon 7 (c.702_703 del AC, p. H233 fs\*1).

When we compared the prevalence of somatic mutations in the group of ATC and PDTC cases we found that *TP53* mutations, as well as *PTEN* mutations, were present in ATC but not in PDTC. Moreover, it is worth to note that complex mutations were found only in ATC. At variance, no major differences were observed in the prevalence of other gene alterations between the two tumoral histotypes. Finally, the prevalence of heterogeneity (i.e., cases with \>2 mutations) was significantly higher in the ATC group (6/21, 28.6%) than in the PDTC group (1/21, 4.7%) (P=0.03).

The presence of a germline mutation was excluded in 6/6 cases whose normal thyroid tissue and/or blood was available.

### Analysis of macrophagic infiltration in ATC and PDTC

Analysis of TAM was performed by evaluating the CD68 expression by IHC. Twenty-six cases (15 ATC and 11 PDTC) whose paraffin embedded tissues were available, were evaluated. All samples turned out to be positive for CD68 although at a variable degree ([Fig. 2A-C](#f2-ol-0-0-8470){ref-type="fig"}). In particular among PDTC the CD68 staining was high in 2 cases, and low in the remaining 9 cases; among ATC the CD68 staining was high in 11 cases, medium in 3 cases and low in 1 case. When comparing the intensity of CD68 staining in ATC and PDTC we found that ATC were characterized by a higher macrophagic infiltration (P=0.0005) ([Fig. 2D](#f2-ol-0-0-8470){ref-type="fig"}). Moreover, in ATC the intensity of CD68 staining correlated with the presence of *TP53* mutations even if, although very close, this correlation did not reach a formal statistical significance ([Fig. 2E](#f2-ol-0-0-8470){ref-type="fig"}, P=0.05).

### Correlation of somatic alterations with the outcome

We correlated the presence of the somatic alterations with the outcome of PDTC and ATC patients. When considering the whole group, data on the outcome of patients were available in 34 cases (17 PDTC and 17 ATC). Among them, 28 patients were died for the tumor, 4 have persistent disease and 2 have been cured and still alive. It is worth to note that these latter patients were both affected by ATC (confirmed by 3 different pathologists) but negative for all studied mutations.

In our series 19/19 (100%) patients with at least 1 somatic mutation died for the disease (ATC n=12, PDTC n=7) while in the group of non mutated cases only 9/15 (60%) were died (ATC n=3, PDTC n=6). The remaining non mutated cases 6/15 (40%) patients were either cured (2/15, 13.3%) (ATC n=2) or affected by a persistent disease (4/15, 26.7%) (PDTC n=4). When analyzing the overall survival length we observed that in the whole series a shorter survival was significantly correlated with the presence of more than 2 gene mutations in the same tissue ([Fig. 3A](#f3-ol-0-0-8470){ref-type="fig"}) Moreover, the absence of *TP53* mutation appears to be a good prognostic factor for a longer survival ([Fig. 3B](#f3-ol-0-0-8470){ref-type="fig"}).

Discussion
==========

ATC and PDTC are rare dedifferentiated thyroid tumors that are supposed to derive either by pre-existing well differentiated thyroid carcinomas ([@b24-ol-0-0-8470]) or to originate directly from normal follicular thyroid cells ([@b25-ol-0-0-8470]). Both of them are very aggressive but the ATC have a worse prognosis in terms of shortness of survival ([@b4-ol-0-0-8470],[@b5-ol-0-0-8470]) and also in the modality of death which is by suffocation in the majority of cases ([@b26-ol-0-0-8470]). The differential diagnosis is very important at clinical level since the medical decisions to be taken are very depending from histology mainly because PDTC can be treated with tyrosine kinase inhibitors, such as sorafenib and lenvatinib ([@b27-ol-0-0-8470],[@b28-ol-0-0-8470]), while these drugs are not yet approved for the treatment of ATC.

In the present series we found that our ATC and PDTC, which were classified and distinguished according to the WHO and Turin classifications, respectively, were represented by two groups of patients with a different clinical and pathological profile already at the time of the diagnosis. Although mean age of patients was already \>60 in both groups, the PDTC group showed a younger age at diagnosis than ATC (median age 58 vs. 67 years). Moreover, the stage IVC at diagnosis, the only one comparable since ATC are all stage IV by definition, was more frequent in ATC (11/17; 64.7%) than in PDTC (1/17; 5.9%). Finally, although the rate of death was high in both in ATC and PDTC (i.e., 82.3 vs. 76.5%, respectively), the length of survival of the dead patients was significantly longer in PDTC (median 47 months) than in ATC (median 6 months). Our findings are in keeping with those reported in the literature since it is known that PDTC, although lethal in the majority of cases, have a slower aggressiveness than ATC and are characterized by a lower stage at presentation and longer follow up ([@b2-ol-0-0-8470],[@b5-ol-0-0-8470]). In our opinion, the fact that in our series the two groups maintain these clinical and biological differences among them indirectly supports the truthfulness of the histological classifications used by our pathologists.

As far as the molecular profiles of ATC and PDTC are concerned, both traditional techniques and NGS confirmed a high prevalence of mutations of 'classical' thyroid tumors related oncogenes and/or tumor suppression genes such as *TP53, TERT and BRAF* ([@b12-ol-0-0-8470],[@b14-ol-0-0-8470],[@b15-ol-0-0-8470],[@b29-ol-0-0-8470],[@b30-ol-0-0-8470]). We analysed the most frequent genetic alterations involved in ATC and PDTC tumorigenesis and in particular we analysed those alterations that were found to be prevalent at least in more than 10% of cases ([@b12-ol-0-0-8470]). Also in our series, *TERT* and *TP53* mutations are the most frequent in ATC histotype followed by *BRAF V600E* and *N-RAS* mutations with a prevalence that is almost the half of that found in the Landa *et al* study. A likely reason to explain this difference can be found in the fact that the NGS method used by Landa *et al* is much more sensitive than the Sanger sequencing method used by us and since, as we also observed, ATC tissues are reach of macrophages, their presence can further reduce the sensitivity in detecting gene mutations. However, at variance, the prevalence of *PTEN* alterations in our ATC series (19%) was very similar to that found by Landa *et al* (18%) thus raising the question of whether we had a real problem of low sensitivity or whether our series of ATC were somehow different from those analysed by Landa *et al*, although in both series the WHO 2004 classification was used.

Regarding the PDTC gene alterations we confirmed that also in our series *TERT* alterations were the most frequent followed by *BRAFV600E* and *N-RAS* with a prevalence that was again about half of that found by Landa *et al*. A peculiar data is that we did not find any alteration of *TP53* and *PTEN* in our series of PDTC and this finding is in contrast with data reported by NGS ([@b12-ol-0-0-8470]) and other studies ([@b29-ol-0-0-8470],[@b31-ol-0-0-8470],[@b32-ol-0-0-8470]) that showed the presence of *TP53* mutations in 8--28% of PDTC cases. One possible explanation to justify this difference is that the differential diagnosis between PDTC and ATC is dependent from pathologists and type of classifications. Italian PDTC cases were diagnosed taking into consideration the Turin classification and Landa\'s PDTC cases were classified taking into consideration either the Turin classification or their own (MSK) criteria. As shown in the Landa\'s paper ([@b12-ol-0-0-8470]) the genetic profile of PDTC tumor is different according to the different system of classification and this could also justify the different prevalence of *TP53* and *PTEN* mutations in our cases.

Another difference that we observed between ATC and PDTC genetic profile is related to the presence of both a higher number of mutated cases and a higher number of heterogeneous cases with \>2 mutations in the same tumor. This finding is in keeping with that of Landa and colleagues that also showed that the median number of Single Nucleotide Variants in ATC is higher than in PDTC ([@b12-ol-0-0-8470]). Cases with a number of mutation \>2 showed a worse prognosis in our overall series and the evidence that the number of cases with multiple mutations is higher in ATC confirmed that these are much more aggressive than PDTC. This finding is in line with the evidence that human tumors with a higher degree of heterogeneity, such as pancreatic tumors, are more aggressive ([@b33-ol-0-0-8470],[@b34-ol-0-0-8470]). As far as the correlation between the mutations and the clinical course of the disease was concerned, we found that patients with tumors positive for *TP53* mutation, that must be underlined were all ATC, had a shorter survival time, as observed also in other human cancer ([@b35-ol-0-0-8470]--[@b37-ol-0-0-8470]). However, their final outcome (i.e. dead vs. alive patients) did not show any statistically significant differences in the *TP53* positive vs. negative cases. It is worth noting that the 2 cured patients, although affected by well ascertained ATC, were both negative for any mutation.

A clear distinction between ATC and PDTC has also been highlighted by differences in the level of TAM infiltrating the tumors. In fact, although all cases, both ATC and PDTC, turned out to be positive for CD68 immunostaining, a higher percentage of CD68 positive cells was demonstrated in ATC with respect to PDTC. The correlation between tumor progression and presence of TAM has been previously reported in thyroid tumors ([@b19-ol-0-0-8470]) and a correlation between TAM, tumor vascularization and metastases has been demonstrated also in other human tumors ([@b16-ol-0-0-8470],[@b38-ol-0-0-8470]). A significant correlation of higher levels of TAM expression has been observed in our *TP53* positive cases, that were only ATC, in keeping with the observation that mutations in this gene may support a pro-inflammatory tumor microenvironment promoting tumor malignancy ([@b39-ol-0-0-8470]). To our knowledge this is the first study demonstrating a correlation between *TP53* and presence and intensity of TAM in ATC.

We are aware of the limits of this study due to the low number of cases and the incompleteness of some data but, unfortunately (or fortunately) these tumors are very rare also in referral centers like ours and the collection of the samples was in 10 years during which the strategies of therapy (i.e., surgery vs. non surgery) and follow up (i.e., periodical active controls vs. palliative care) of these patients have been changing and impacting on the outcome of these patients. Only a multicentric study with shared protocols of therapy and follow up could overcome this problem.

Despite these considerations, according to our results and taking into account the limit above mentioned, we can conclude that ATC and PDTC, although both of them still lethal, are different tumors not only because characterized by a different clinical and pathological profile at diagnosis but also, at least in our series, because they show a different molecular profile in terms of type and number of mutations and also a different spectrum of positivity for TAM. New targeted therapies for both, and in particular for PDTC, can provide a chance of prolonged survival. Finally, according to our results, the WHO classification for ATC and the Turin classification for PDTC are likely those that better distinguish the two types of very aggressive thyroid cancer.

This study was supported by the Associazione Italiana Ricerca sul Cancro (AIRC, Investigator grant 2014, project code 15431).
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###### 

PCR conditions and primers sequence used for the amplification of putative oncogenes involved in thyroid cancer.

  Gene     Exons      5′→3′ Sequence                 Tm      Lenght   Gene    Exons    5′→3′ Sequence                Tm   Lenght
  -------- ---------- ------------------------------ ------- -------- ------- -------- ----------------------------- ---- --------
  CTNNB1   EX3        TCACTGAGCTAACCCTGGCTAT         60      497      TERT    EX2      CTACTCCTCAGGCGACAAGG          60   197
                      TCTCTTTTCTTCACCACAACATTT                                         CAAGCAGCTCCAGAAACAGG               
  PIK3CA   EX10       TGCTTTTTCTGTAAATCATCTGTGA      61      285      AKT     EX1      TAGAGTGTGCGTGGCTCTCA          60   171
                      TGCTGAGATCAGCCAAATTC                                             CGCCACAGAGAGAAGTTGTTGA             
           EX20       TGACATTTGAGCAAAGACCTG          60      387      H-RAS   EX2      GTGGGTTTGCCCTTCAGAT           60   325
                      TGTGGAATCCAGAGTGAGCTT                                            CCTATCCTGGCTGTGTCCTG               
  TP53     EX5/6      CACTTGTGCCCTGACTTTCA           Touch   464      H-RAS   EX3      AGAGGCTGGCTGTGTGAACT          60   344
                      CTTAACCCCTCCTCCCAGAG           70/55                             ACATGCGCAGAGAGGACAG                
           EX7        CTTGGGCCTGTGTTATCTCC           Touch   228      N-RAS   EX2      GAAAGCTTTAAAGTACTGTAGATGTGG   60   240
                      TGGAAGAAATCGGTAAGAGGTG         70/55                             CCGACAAGTGAGAGACAGGA               
           EX8/9      CAAGGGTGGTTGGGAGTAGA           Touch   545      N-RAS   EX3      TTGCATTCCCTGTGGTTTTT          60   325
                      ACCAGGAGCCATTGTCTTTG           70/55                             TGGTAACCTCATTTCCCCATA              
  PTEN     ex5        TGCAACATTTCTAAAGTTACCTACTTG    60      397      K-RAS   EX2      TTAACCTTATGTGTGACATGTTCTAA    60   230
                      AAACCCAAAATCTGTTTTCCAA                                           ATCAAAGAATGGTCCTGCAC               
           ex6        GGCTACGACCCAGTTACCAT           60      347      K-RAS   EX3      TCAAGTCCTTTGCCCATTTT          60   375
                      CCTGCATAAATTTCAAATGTGG                                           TGCATGGCATTAGCAAAGAC               
           ex7        TCCATATTTCGTGTATATTGCTGA       60      397      ALK     EX23     TTCCTCCCAGTTTAAGATTTGC        60   298
                      GCAAAACACCTGCAGATCTAA                                            CATCGAGGAACTTGCTACCC               
           ex8        TGATAGTTTATTTTGTTGACTTTTTGC    60      452      EML4/   EX23/0   GTGCAGTGTTTAGCATTCTTGGGG      60   244
                      GTCAAGCAAGTTCTTCATCAGC                          ALK     EX2      TGCCAGCAAAGCAGTAGTTG               
  BRAF     EX15       TTGACTCTAAGAGGAAAGATGAAGTACT   60      320      STRN/   EX3/     CGGGACAGAATTGAATCAGGG         60   244
                      AGCATCTCAGGGCAAAAAT                             ALK     EX20     TGCCAGCAAAGCAGTAGTTG               
  TERT     Promoter   CTGGCGTCCCTGCACCCTGG           62      474      ALK     EX27/    ACCCAAGAACTGCCCTGG            60   233
                      ACGAACGTGGCCAGCGGCAG           Q-SOL                    EX29     GAGAGACCAGGAGAGGAGGA               

PCR, polymerase chain reaction; Tm, melting temperature.

###### 

Genetic alterations in our series (n=42) of ATC and PDTC cases.

  Gene            Mutation                          Exon       Mutated cases in ATC (n=21)   Mutated cases in PDTC (n=21)   P (χ^2^)
  --------------- --------------------------------- ---------- ----------------------------- ------------------------------ ----------
  NRAS            Q61R                              3            2 (9.5%)                    1 (4.7%)                       NS
  BRAF            V600E                             15         4 (19%)                       4 (19%)                        NS
  AKT             E17K                              1          0                             1 (4.7%)                       NS
  TP53            C176Y                             5          1 (4.75%)                     0                              0.0003
                  H179R                                        1 (4.75%)                     0                              
                  c.572_574delCTC, P191delP         6          1 (4.75%)                     0                              
                  M246L                             7          1 (4.75%)                     0                              
                  R248W                                        1 (4.75%)                     0                              
                  c.702_703 del AC, p. H233 fs\*1              1 (4.75%)                     0                              
                  R267W                             8          1 (4.75%)                     0                              
                  R273C                                        1 (4.75%)                     0                              
                  R273H                                        1 (4.75%)                     0                              
                  K320N                             9          1 (4.75%)                     0                              
  PIK3CA          E545K                             10         1 (4.75%)                     0                              NS
                  H1047R                            20         0                             1 (4.7%)                       
  PTEN            c.355delG, p. V119Lfs\*15                                                                                 
                  Q97R                              5          1 (4.75%)                     0                              0.03
                  D115N                                        1 (4.75%)                     0                              
                  S170I                             6          1 (4.75%)                     0                              
                  c.741_742insA, p. P248fs\*5       7          1 (4.75%)                     0                              
  TERT            C250T                             Promoter   1 (4.75%)                     0                              NS
                  C228T                                        7 (33%)                       9 (43%)                        
                  P376A                             2          0                               1 (4.7%)                     
  ALK             EML4/ALK rearrangement            14/20      0                             1/9 (11.1%)                    NS
  n\. mutations   \>2                                            6 (28.6%)                     1 (4.7%)                     0.03
                  ≤2                                           15 (71.4%)                    20 (95.3%)                     

ATC, anaplastic thyroid cancer; PDTC, poorly differentiated thyroid cancer; NS, not significant.
